Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
From - Diagnostic Testing & Emerging Technologies
So far, 2017 is proving to be a good year for fundraising and investment in the broad health care industry, according to report by…
By Lâle White bio
As XIFIN predicted, the PAMA reporting exercise has resulted in significant proposed laboratory fee cuts. In fact…
US oncology patients are missing out on targeted therapies due to a combination of testing "quality gaps" and slow test diffusion
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) recently unveiled its FY 2015-2016: Regulatory Science Progress Report. The report, the second of its kind under the…
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) is plagued with chronic understaffing, scrutiny over the length of time for approvals, and an expanding workload, while also…
From - Diagnostic Testing & Emerging Technologies
While much attention is focused on using genomic markers to target the effectiveness of treatments, simultaneous research is exploring use of genomic markers to…